• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

Wellcome renews partnership with DNDi to develop new generation drugs to treat leishmaniasis

Home > Press releases

Wellcome renews partnership with DNDi to develop new generation drugs to treat leishmaniasis

Lab activities
GENEVA / LONDON — 6 Jul 2022
  • English
    • English
    • Español
    • Português

The UK charitable foundation Wellcome has awarded a €5.7 million grant to the non-profit medical research organization Drugs for Neglected Diseases initiative (DNDi) to continue the development of promising oral new chemical entities to treat leishmaniasis, one of the world’s most devastating parasitic diseases.

Leishmaniasis is the deadliest parasitic killer after malaria. It is endemic in 98 countries with over one billion people at risk globally and between 700,000 and 1 million new cases estimated annually. The most severe form, visceral leishmaniasis, is fatal if untreated. Its cutaneous form can cause disfigurement and permanent scarring, leading to social stigmatization and mental health issues, especially for women. Half of people affected are children under 15. 

‘Leishmaniasis is a deeply neglected disease that affects the poorest communities. Existing treatments are not good enough: most are outdated, require painful injections, and have serious toxicities and variable efficacy. Patients deserve better. That is why we are excited to renew our collaboration with Wellcome, which will allow us to continue to develop promising molecules for safe, effective and easy-to-administer oral drugs,’ said Dr Fabiana Alves, Director of NTDs (Neglected Tropical Diseases) Leishmaniasis and Mycetoma at DNDi. 

DNDi, in partnership with Wellcome and others, has developed in recent years a large and unique portfolio of new chemical entities (NCEs) that includes a total of five NCEs advancing to pre-clinical and Phase I clinical trials, and the lead compound LXE408 which is advancing to Phase II trials. LXE408 was discovered at pharmaceutical company Novartis with financial support from Wellcome and is being developed jointly by DNDi and Novartis. 

The renewed partnership will build on a successful project by Wellcome and DNDi entitled ‘21st century treatments for sustainable elimination of leishmaniasis’ that started in 2018. The renewed project aims at continuing the development of the new drugs, including progressing LXE408 to Phase II clinical trials. The long-term objective is to develop up to five oral therapies for visceral leishmaniasis and cutaneous leishmaniasis in Asia, Africa, and Latin America: the most promising candidates will progress towards Phase III clinical studies, with industrial scale-up and registration in disease-endemic regions. 

‘Our intent is that the future treatments that we are developing will cater to the needs of these neglected patients, especially children who represent half of visceral leishmaniasis cases. If they are oral and well-tolerated, they could be deployed within primary healthcare systems, which will allow a higher number of people to receive early treatment,’ said Dr Alves. ‘That will contribute to the sustainable elimination efforts against VL in Asia, as well as disease control in Africa and Latin America, and will contribute to control of cutaneous leishmaniasis worldwide.’ 

Leishmaniasis is strongly associated with poverty, poor access to healthcare, and conflict. The forced displacement of non-immune migrants to endemic areas caused visceral leishmaniasis epidemics during conflict in South Sudan in the 1990s and in 2010, as well the more recent outbreak of cutaneous leishmaniasis in Syria. The COVID-19 pandemic has disrupted visceral leishmaniasis control efforts. 

Moreover, leishmaniasis is a climate-sensitive disease. Changes in temperatures and rain patterns impact the survival and distribution of sandflies that transmit the disease, which in turn will facilitate the parasite’s transmission in previously non-endemic areas. Health systems need to be prepared and a simple oral treatment would be better adapted to meet these upcoming challenges. 

The new treatments developed thanks to this grant could also benefit patients presenting with complex forms of leishmaniasis, such as visceral leishmaniasis and HIV co-infected individuals, muco-cutaneous and post-kala-azar dermal leishmaniasis (PKDL). The programme contributes actively to the World Health Organization Roadmap for NTDs, calling for user-friendly, safe, and highly efficacious treatments. 

About Wellcome  

Wellcome supports science to solve the urgent health challenges facing everyone. We support discovery research into life, health and wellbeing, and we’re taking on three worldwide health challenges: mental health, infectious disease and climate and health. 

About DNDi

A not-for-profit research and development organization, DNDi  works to deliver new treatments for neglected patients, those living with Chagas disease, sleeping sickness (human African trypanosomiasis), leishmaniasis, filarial infections, mycetoma, paediatric HIV, and hepatitis C. DNDi is also coordinating the ANTICOV clinical trial to find treatments for mild-to-moderate COVID-19 cases in Africa. Since its inception in 2003, DNDi has delivered twelve new treatments to date, including new drug combinations for kala-azar, two fixed-dose antimalarials, and DNDi’s first successfully developed new chemical entity, fexinidazole, approved in 2018 for the treatment of both stages of sleeping sickness.  dndi.org

Media contact

Frédéric Ojardias
fojardias@dndi.org
Phone: +41 79 431 6216

Photo credit: Maneesh Agnihotri-DNDi

Funding Cutaneous leishmaniasis Visceral leishmaniasis

Read, watch, share

Loading...
Statements
27 May 2025

DNDi interventions at the 78th World Health Assembly

Press releases
22 May 2025

Six African nations commit to eliminate deadly neglected disease visceral leishmaniasis

Videos
20 May 2025

The Children of the Sierra

Press releases
13 May 2025

First all-oral treatment for a rare but deadly strain of sleeping sickness now available and being used to treat patients in endemic countries in Africa

Statements
8 May 2025

DNDi’s briefing note for 78th World Health Assembly

Marco Krieger
News
30 Apr 2025

Message on the passing of Dr Marco Aurélio Krieger, Vice-President of Production and Innovation in Health, Fiocruz

Screening activities in village in Guinea
News
25 Apr 2025

Statements from Dr Luis Pizarro and Daisuke Imoto about the Hideyo Noguchi Africa Prize awarded to DNDi

Two man outside of a hospital talking with a nurse
Press releases
24 Apr 2025

Liverpool clinical trial aims to advance life-changing treatment for a deadly parasitic disease

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License